Lyrica

Lyrica

pregabalin

Manufacturer:

Pfizer

Distributor:

Zuellig Pharma
Full Prescribing Info
Contents
Pregabalin.
Description
Each capsule also contains the following excipients: Capsule Content: Lactose monohydrate, maize starch and talc. Capsule Shell: Gelatin, titanium dioxide (E171), sodium laurylsulfate, anhydrous colloidal silica, purified water. Printing Ink: Shellac, black iron oxide (E172), propylene glycol, potassium hydroxide.
Pregabalin is a γ-aminobutyric acid analogue, [(S)-3-(aminomethyl)-5-methylhexanoic acid].
Action
Pharmacology: Pharmacodynamics: Mechanism of Action: Pregabalin binds to an auxiliary subunit (α2-δ protein) of voltage-gated calcium channels in the central nervous system.
Evidence from animal models with nerve damage has shown that pregabalin reduces calcium dependent release of pro-nociceptive neurotransmitters in the spinal cord possibly by disrupting calcium trafficking and/or reducing calcium currents. Evidence from other animal models of nerve damage suggests the antinociceptive activities of pregabalin may also be mediated through interactions with the descending noradrenergic and serotonergic pathways.
Clinical Experience: Neuropathic Pain: Efficacy has been shown in studies in diabetic neuropathy and post-herpetic neuralgia. Efficacy has not been studied in other models of neuropathic pain. Pregabalin has been studied in 9 controlled clinical studies of up to 13 weeks with twice daily dosing and up to 8 weeks with 3 times daily dosing. Overall, the safety and efficacy profiles for twice-daily and 3 times daily dosing regimens were similar. In clinical trials up to 13 weeks, a reduction in pain was seen by week 1 and was maintained throughout the treatment period.
In controlled clinical trials, 35% of the pregabalin-treated patients and 18% of the patients on placebo had a 50% improvement in pain score. For patients not experiencing somnolence, such an improvement was observed in 33% of patients treated with pregabalin and 18% of patients on placebo. For patients who experienced somnolence, the responder rates were 48% on pregabalin and 16% on placebo.
Epilepsy: Pregabalin has been studied in 3 controlled clinical studies of 12-week duration with either twice-daily or 3 times daily dosing. Overall, the safety and efficacy profiles for twice-daily and 3 times daily dosing regimens were similar.
A reduction in seizure frequency was observed by week 1.
Generalized Anxiety Disorder (GAD): Pregabalin has been studied in 6 controlled studies of 4-6 weeks duration, an elderly study of 8-week duration and a long-term relapse prevention study with a double blind relapse prevention phase of 6 months duration.
Relief of the symptoms of GAD as reflected by the Hamilton Anxiety Rating Scale (HAM-A) was observed by week 1.
In controlled clinical trials (4-8 week duration), 52% of the pregabalin-treated patients and 38% of the patients on placebo had at least a 50% improvement in HAM-A total score from baseline to endpoint.
Fibromyalgia: Pregabalin as monotherapy has been studied in 5 placebo-controlled studies, 3 of 12 weeks fixed-dose duration, 1 of 7 weeks fixed-dose duration and a 6-month study demonstrating long-term efficacy. Pregabalin treatment in all fixed-dose studies produced a significant reduction in pain associated with fibromyalgia at doses from 300-600 mg twice daily.
In the three 12-week fixed-dose studies, 40% of pregabalin-treated patients experienced a ≥30% improvement in pain score versus 28% of the patients on placebo; 23% of treated patients experienced a ≥50% improvement in pain score versus 15% of the patients on placebo.
Pregabalin produced significantly superior global assessment scores via the Patient Global Impression of Change (PGIC) in the three 12-week fixed-dose studies as compared to placebo treatment. (41% patients feeling very much or much improved on pregabalin versus 29% on placebo.) As measured by Fibromyalgia Impact Questionnaire (FIQ), pregabalin produced a statistically significant improvement in function versus placebo treatment in 2 out of the 3 fixed-dose studies in which it was evaluated.
Pregabalin treatment produced significant improvements in patient reported sleep outcomes in the 4 fixed-dose studies as measured by Medical Outcomes Study Sleep Scale (MOS-SS) sleep disturbance subscale, MOS-SS overall sleep problem index and the daily sleep quality diary.
In the 6-month study, improvement in pain, global assessment (PGIC), function (FIQ total score) and sleep (MOS-SS sleep disturbance subscale) were maintained for pregabalin-treated patients for a significantly longer period compared to placebo.
Pregabalin 600 mg/day showed an additional improvement in patient reported sleep outcomes as compared to 300 and 450 mg/day; mean effects on pain, global assessment and FIQ were similar at 450 and 600 mg/day, although the 600 mg/day dose was less well tolerated.
Pharmacokinetics: Pregabalin steady-state pharmacokinetics is similar in healthy volunteers, patients with epilepsy receiving antiepileptic drugs and patients with chronic pain.
Absorption: Pregabalin is rapidly absorbed when administered in the fasted state, with peak plasma concentrations occurring within 1 hr following both single and multiple dose administration. Pregabalin oral bioavailability is estimated to be ≥90% and is independent of dose. Following repeated administration, steady state is achieved within 24-48 hrs. The rate of pregabalin absorption is decreased when given with food resulting in a decrease in Cmax by approximately 25-30% and a delay in tmax to approximately 2.5 hrs. However, administration of pregabalin with food has no clinically significant effect on the extent of pregabalin absorption.
Distribution: In preclinical studies, pregabalin has been shown to cross the blood brain barrier in mice, rats and monkeys.
Pregabalin has been shown to cross the placenta in rats and is present in the milk of lactating rats. In humans, the apparent volume of distribution of pregabalin following oral administration is approximately 0.56 L/kg. Pregabalin is not bound to plasma proteins.
Metabolism: Pregabalin undergoes negligible metabolism in humans. Following a dose of radiolabelled pregabalin, approximately 98% of the radioactivity recovered in the urine was unchanged pregabalin. The N-methylated derivative of pregabalin, the major metabolite of pregabalin found in urine, accounted for 0.9% of the dose. In preclinical studies, there was no indication of racemisation of pregabalin S-enantiomer to the R-enantiomer.
Elimination: Pregabalin is eliminated from the systemic circulation primarily by renal excretion as unchanged drug. Pregabalin mean elimination half-life is 6.3 hrs. Pregabalin plasma clearance and renal clearance are directly proportional to creatinine clearance (see Renal Impairment as follows).
Dosage adjustment in patients with reduced renal function or undergoing hemodialysis is necessary (see table under Dosage & Administration).
Linearity/Nonlinearity: Pregabalin pharmacokinetics is linear over the recommended daily dose range. Intersubject pharmacokinetic variability for pregabalin is low (<20%). Multiple dose pharmacokinetics is predictable from single-dose data. Therefore, there is no need for routine monitoring of plasma concentrations of pregabalin.
Pharmacokinetics in Special Patient Groups: Gender: Clinical trials indicate that gender does not have a clinically significant influence on the plasma concentrations of pregabalin.
Renal Impairment: Pregabalin clearance is directly proportional to creatinine clearance. In addition, pregabalin is effectively removed from plasma by hemodialysis (following a 4-hr hemodialysis treatment, plasma pregabalin concentrations are reduced by approximately 50%). Because renal elimination is the major elimination pathway, dosage reduction in patients with renal impairment and dosage supplementation following hemodialysis is necessary (see table under Dosage & Administration).
Hepatic Impairment: No specific pharmacokinetic studies were carried out in patients with impaired liver function. Since pregabalin does not undergo significant metabolism and is excreted predominantly as unchanged drug in the urine, impaired liver function would not be expected to significantly alter pregabalin plasma concentrations.
Elderly (>65 years): Pregabalin clearance tends to decrease with increasing age. This decrease in pregabalin oral clearance is consistent with decreases in creatinine clearance associated with increasing age. Reduction of pregabalin dose may be required in patients who have age-related compromised renal function (see table under Dosage & Administration).
Toxicology: Preclinical Safety Data: In conventional safety pharmacology studies in animals, pregabalin was well tolerated at clinically relevant doses. In repeated dose toxicity studies in rats and monkeys, CNS effects were observed, including hypoactivity, hyperactivity and ataxia. An increased incidence of retinal atrophy commonly observed in aged albino rats was seen after long-term exposure to pregabalin at exposures ≥5 times the mean human exposure at the maximum recommended clinical dose.
Teratogenicity: Pregabalin was not teratogenic in mice, rats or rabbits. Fetal toxicity in rats and rabbits occurred only at exposures sufficiently above human exposure. In prenatal/postnatal toxicity studies, pregabalin-induced offspring developmental toxicity in rats at exposures >2 times the maximum recommended human exposure.
Mutagenicity: Pregabalin is not genotoxic based on results of a battery of in vitro and in vivo tests.
Carcinogenicity: Two-year carcinogenicity studies with pregabalin were conducted in rats and mice. No tumors were observed in rats at exposures up to 24 times the mean human exposure at the maximum recommended clinical dose of 600 mg/day. In mice, no increased incidence of tumors was found at exposures similar to the mean human exposure, but an increased incidence of haemangiosarcoma was observed at higher exposures. The non-genotoxic mechanism of pregabalin-induced tumor formation in mice involves platelet changes and associated endothelial cell proliferation. These platelet changes were not present in rats or in humans based on short-term and limited long-term clinical data. There is no evidence to suggest an associated risk to humans.
In juvenile rats, the types of toxicity do not differ qualitatively from those observed in adult rats. However, juvenile rats are more sensitive. At therapeutic exposures, there was evidence of CNS clinical signs of hyperactivity and bruxism and some changes in growth (transient body weight gain suppression). Effects on the estrus cycle were observed at 5-fold the human therapeutic exposure.
Neurobehavioral/cognitive effects were observed in juvenile rats 1-2 weeks after exposure >2 times (acoustic startle response) or >5 times (learning/memory) the human therapeutic exposure. Reduced acoustic startle response was observed in juvenile rats 1-2 weeks after exposure at >2 times the human therapeutic exposure. Nine (9) weeks after exposure, this effect was no longer observable.
Indications/Uses
Treatment of central and peripheral neuropathic pain in adults which includes diabetic peripheral neuropathy and post-herpetic neuralgia; as adjunctive therapy in adults with partial seizures with or without secondary generalization; treatment of generalized anxiety disorder (GAD) in adults; management of fibromyalgia.
Dosage/Direction for Use
Dose Range: 150-600 mg/day given in either 2 or 3 divided doses.
Pregabalin may be taken with or without food.
Neuropathic Pain: Recommended Starting Dose: 150 mg/day. Based on individual patient response and tolerability, the dosage may be increased to 300 mg/day after an interval of 3-7 days, and if needed, to a maximum dose of 600 mg/day after an additional 7-day interval.
Epilepsy: Recommended Starting Dose: 150 mg/day. Based on individual patient response and tolerability, the dosage may be increased to 300 mg/day after 1 week. The maximum dosage of 600 mg/day may be achieved after an additional week.
Generalized Anxiety Disorder: Dose Range: 150-600 mg/day given as 2-3 divided doses. The need for treatment should be reassessed regularly.
Pregabalin treatment can be started with a dose of 150 mg/day. Based on individual patient response and tolerability, the dosage may be increased to 300 mg/day after 1 week. Following an additional week, the dose may be increased to 450 mg/day. The maximum dose of 600 mg/day may be achieved after an additional week.
Fibromyalgia Syndrome: Recommended Dose: 300-450 mg/day given in 2 divided doses. Some patients may derive additional benefit at 600 mg/day. Dosing should begin at 75 mg twice daily (150 mg/day) and may be increased to 150 mg twice daily (300 mg/day) within 1 week based on efficacy and tolerability. Patients who do not experience sufficient benefit with 300 mg/day may be further increased to 225 mg twice daily (450 mg/day). If needed, in some patients, based on individual response and tolerability, the dose may be increased to maximum dosage of 600 mg/day after an additional week.
Discontinuation of Pregabalin: If pregabalin has to be discontinued, it is recommended that this should be done gradually over a minimum of 1 week.
Patients with Renal Impairment: Dosage reduction in patients with the compromised renal function must be individualized according to creatinine clearance (ClCr), (see Pharmacokinetics: Pharmacokinetics in Special Patient Groups: Renal Impairment under Actions) as indicated in the table determined using the following formula. See equation.

Click on icon to see table/diagram/image

For patients receiving hemodialysis, the pregabalin daily dose should be adjusted based on renal function. In addition to the daily dose, a supplementary dose should be given immediately following every 4-hr hemodialysis treatment (see table).

Click on icon to see table/diagram/image

Patients with Hepatic Impairment: No dosage adjustment is required for patients with hepatic impairment (see Pharmacokinetics: Pharmacokinetics in Special Patient Groups: Hepatic Impairment under Actions).
Children and Adolescents (12-17 years): The safety and effectiveness of pregabalin in pediatric patients <12 years and adolescents has not been established. The use in children is not recommended (see Toxicology: Preclinical Safety Data under Actions).
Elderly (>65 years): Elderly patients may require a dose reduction of pregabalin due to decreased renal function (see Pharmacokinetics: Pharmacokinetics in Special Patient Groups: Elderly >65 years under Actions).
Overdosage
In overdoses up to 15 g, no unexpected adverse reactions were reported.
Symptoms: In the post-marketing experience, the most commonly reported adverse events observed when pregabalin was taken in overdose included affective disorder, somnolence, confusional state, depression, agitation and restlessness.
Treatment: Treatment of pregabalin overdose should include general supportive measures and may include hemodialysis if necessary (see table under Dosage & Administration).
Contraindications
Hypersensitivity to pregabalin or to any of the excipients of Lyrica.
Special Precautions
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take Lyrica.
Some diabetic patients who gain weight on pregabalin treatment may need to adjust hypoglycemic medications.
There have been reports in the post-marketing experience of hypersensitivity reactions, including cases of angioedema. Pregabalin should be discontinued immediately if symptoms of angioedema eg, facial, perioral or upper airway swelling occur.
Pregabalin treatment has been associated with dizziness and somnolence, which could increase the occurrence of accidental injury (fall) in the elderly population. There have also been post-marketing reports of loss of consciousness, confusion and mental impairment. Therefore, patients should be advised to exercise caution until they are familiar with the potential effects of the medication.
In the post-marketing experience, transient visual blurring and other changes in visual acuity have been reported in patients treated with pregabalin. Discontinuation of pregabalin may result in resolution or improvement of these visual symptoms.
There are insufficient data for the withdrawal of concomitant antiepileptic medicinal products, once seizure control with pregabalin in the add-on situation has been reached, in order to reach monotherapy on pregabalin.
After discontinuation of short-term and long-term treatment with pregabalin, withdrawal symptoms have been observed in some patients. The following events have been mentioned: Insomnia, headache, nausea, anxiety, hyperhidrosis and diarrhea.
Although the effects of discontinuation on the reversibility of renal failure have not been systematically studied, improved renal function following discontinuation or dose reduction of pregabalin has been reported.
Although there has been no causal relationship identified between exposure to pregabalin and congestive heart failure, there have been post-marketing reports of congestive heart failure in some patients receiving pregabalin. In short-term trials of patients without clinically significant heart or peripheral vascular disease, there was no apparent association between peripheral edema and cardiovascular complications eg, hypertension or congestive heart failure. Because there are limited data on severe congestive heart failure patients, pregabalin should be used with caution in these patients (see Adverse Reactions).
Effects on the Ability to Drive or Operate Machinery: Pregabalin may cause dizziness and somnolence and therefore may influence the ability to drive or use machines. Patients are advised not to drive, operate complex machinery or engage in other potentially hazardous activities until it is known whether Lyrica affects their ability to perform these activities.
Use in Pregnancy & Lactation: There are no adequate data from the use of pregabalin in pregnant women.
Studies in animals have shown reproductive toxicity (see Toxicology: Preclinical Safety Data under Actions). The potential risk for humans is unknown. Therefore, pregabalin should not be used during pregnancy unless the benefit to the mother clearly outweighs the potential risk to the fetus. Effective contraception must be used in women of childbearing potential.
It is not known if pregabalin is excreted in the breast milk of humans; however, it is present in the milk of rats. Therefore, breastfeeding is not recommended during treatment with pregabalin.
Use In Pregnancy & Lactation
There are no adequate data from the use of pregabalin in pregnant women.
Studies in animals have shown reproductive toxicity (see Toxicology: Preclinical Safety Data under Actions). The potential risk for humans is unknown. Therefore, pregabalin should not be used during pregnancy unless the benefit to the mother clearly outweighs the potential risk to the fetus. Effective contraception must be used in women of childbearing potential.
It is not known if pregabalin is excreted in the breast milk of humans; however, it is present in the milk of rats. Therefore, breastfeeding is not recommended during treatment with pregabalin.
Adverse Reactions
The pregabalin clinical program involved >12,000 patients who were exposed to pregabalin, of whom >7000 were in double-blind placebo controlled trials. The most commonly reported adverse reactions were dizziness and somnolence. Adverse reactions were usually mild to moderate in intensity. In all controlled studies, the discontinuation rate due to adverse reactions was 14% for patients receiving pregabalin and 5% for patients receiving placebo. The most common adverse reactions resulting in discontinuation from pregabalin treatment groups were dizziness and somnolence.
Selected adverse events that were treatment-related in the pooled analysis of clinical trials are listed by system organ class and frequency: Very common (>1/10), common (>1/100, <1/10), uncommon (>1/1000, <1/100) and rare (<1/1000).
The adverse reactions listed may also be associated with the underlying disease and/or concomitant medications.
Infections and Infestations: Uncommon: Nasopharyngitis.
Blood and Lymphatic System Disorders: Rare: Neutropenia.
Metabolism and Nutrition Disorders: Common: Increased appetite. Uncommon: Anorexia. Rare: Hypoglycemia.
Psychiatric Disorders: Common: Confusion, disorientation, irritability, euphoric mood, decreased libido, insomnia. Uncommon: Depersonalization, anorgasmia, restlessness, depression, agitation, mood swings, depressed mood, word finding difficulty, hallucination, abnormal dreams, increased libido, panic attack, apathy. Rare: Disinhibition, elevated mood.
Nervous System Disorders: Very Common: Dizziness, somnolence. Common: Ataxia, abnormal coordination, balance disorder, amnesia, attention disturbance, memory impairment, tremor, dysarthria, paraesthesia, sedation, lethargy. Uncommon: Cognitive disorder, hypoesthesia, nystagmus, speech disorder, myoclonus, hyporeflexia, dyskinesia, psychomotor hyperactivity, postural dizziness, hyperesthesia, ageusia, burning sensation, intention tremor, stupor, syncope. Rare: Hypokinesia, parosmia, dysgraphia.
Eye Disorders: Common: Blurred vision, diplopia. Uncommon: Visual disturbance, visual field defect, dry eye, eye swelling, reduced visual acuity, eye pain, asthenopia, increased lacrimation. Rare: Photopsia, eye irritation, mydriasis, oscillopsia, altered visual depth perception, peripheral vision loss, strabismus, visual brightness.
Ear and Labyrinth Disorders: Common: Vertigo. Rare: Hyperacusis.
Cardiac Disorders: Uncommon: 1st-degree atrioventricular block, tachycardia. Rare: Sinus tachycardia, sinus arrhythmia, sinus bradycardia.
Vascular Disorders: Uncommon: Hypotension, hypertension, flushing, hot flushes, peripheral coldness.
Respiratory, Thoracic and Mediastinal Disorders: Uncommon: Dyspnoea, cough, nasal dryness. Rare: Nasal congestion, epistaxis, rhinitis, snoring, throat tightness.
Gastrointestinal Disorders: Common: Vomiting, abdominal distension, constipation, dry mouth, flatulence. Uncommon: Salivary hypersecretion, gastrooesophageal reflux disease, oral hypoesthesia. Rare: Ascites, dysphagia, pancreatitis.
Skin and Subcutaneous Tissue Disorders: Uncommon: Sweating, papular rash. Rare: Cold sweat, urticaria.
Musculoskeletal and Connective Tissue Disorders: Uncommon: Muscle twitching, joint swelling, muscle cramp, myalgia, arthralgia; back and limb pain; muscle stiffness. Rare: Cervical spasm, neck pain, rhabdomyolysis.
Renal and Urinary Disorders: Uncommon: Dysuria, urinary incontinence. Rare: Oliguria, renal failure.
Reproductive System and Breast Disorders: Common: Erectile dysfunction. Uncommon: Delayed ejaculation, sexual dysfunction. Rare: Amenorrhea; breast pain, discharge and enlargement; dysmenorrhoea.
General Disorders and Administration Site Conditions: Common: Peripheral oedema, oedema, abnormal gait, drunk and abnormal feeling, fatigue. Uncommon: Chest tightness, fall, generalized oedema, pain, chills, asthenia, thirst. Rare: Pyrexia.
Investigations: Common: Increased weight. Uncommon: Increased alanine aminotransferase, blood creatine phosphokinase and aspartate aminotransferase; decreased platelet count. Rare: Increased blood glucose and blood creatinine; decreased blood potassium, weight and white blood cell count.
The following adverse events were reported during post-marketing surveillance: Immune System Disorders: Angioedema, allergic reaction, hypersensitivity.
Nervous System Disorders: Headache, loss of consciousness, mental impairment.
Eye Disorders: Keratitis.
Cardiac Disorders: Congestive heart failure.
Respiratory and Thoracic Disorders: Pulmonary Oedema.
Gastrointestinal Disorders: Swollen tongue, diarrhea, nausea.
Skin and Subcutaneous Tissue Disorders: Face swelling, pruritus.
Renal and Urinary Disorders: Urinary retention.
Reproductive System and Breast Disorders: Gynecomastia.
General Disorders and Administration Site Conditions: Malaise.
Drug Interactions
Since pregabalin is predominantly excreted unchanged in the urine, undergoes negligible metabolism in humans (<2% of a dose recovered in urine as metabolites), does not inhibit drug metabolism in vitro, and is not bound to plasma proteins, it is unlikely to produce, or be subject to, pharmacokinetic interactions.
Accordingly, in in vivo studies, no clinically relevant pharmacokinetic interactions were observed between pregabalin and phenytoin, carbamazepine, valproic acid, lamotrigine, gabapentin, lorazepam, oxycodone or ethanol. Population pharmacokinetic analysis indicated that oral antidiabetics, diuretics, insulin, phenobarbital, tiagabine and topiramate had no clinically significant effect on pregabalin clearance.
Co-administration of pregabalin with the oral contraceptives norethisterone and/or ethinyloestradiol does not influence the steady-state pharmacokinetics of either substance.
Pregabalin may potentiate the effects of ethanol and lorazepam. In controlled clinical trials, multiple oral doses of pregabalin co-administered with oxycodone, lorazepam or ethanol did not result in clinically important effects on respiration. Pregabalin appears to be additive in the impairment of cognitive and gross motor function caused by oxycodone.
In the post-marketing experience, there are reports of respiratory failure and coma in patients taking pregabalin and other CNS depressant medications. There are post-marketing reports of events related to reduced lower gastrointestinal tract function (eg, intestinal obstruction, paralytic ileus, constipation) when pregabalin was co-administered with medications that have the potential to produce constipation eg, opioid analgesics.
No specific pharmacodynamic interaction studies were conducted in elderly volunteers.
Incompatibilities: Not applicable.
Storage
Store at room temperature below 25°C.
ATC Classification
N03AX16 - pregabalin ; Belongs to the class of other antiepileptics.
Presentation/Packing
Cap 25 mg (white, hard gelatin, marked with "Pfizer" on the cap and "PGN 25" on the body with black ink) x 56's. 75 mg (white and orange, hard gelatin, marked with "Pfizer" on the cap and "PGN 75" on the body with black ink) x 56's. 150 mg (white, hard gelatin, marked with "Pfizer" on the cap and "PGN 150" on the body with black ink) x 56's.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in